BridgeBio Pharma News

BridgeBio Pharma | DEFA14A: Others

Apr 25 22:17 ET

BridgeBio Pharma | ARS: Annual Report to Security Holders

Apr 25 16:14 ET

BridgeBio Pharma | DEF 14A: Definitive information statements

Apr 25 16:07 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Kumar Neil

Mar 14 16:05 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Officer STEPHENSON BRIAN C

Mar 14 16:05 ET

BridgeBio Pharma | 424B5: Prospectus

Mar 6 17:21 ET

BridgeBio Pharma | 8-K: Current report

Mar 6 17:16 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Director Scott Randal W.

Mar 5 16:05 ET

BridgeBio Pharma | 424B5: Prospectus

Mar 4 17:51 ET

BridgeBio Pharma | 8-K: Current report

Mar 4 07:05 ET

BridgeBio Pharma | 10-K: Annual report

Feb 22 16:33 ET

BridgeBio Pharma | 8-K: BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Feb 22 07:36 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Kumar Neil

Feb 21 22:41 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Director HOMCY CHARLES J

Feb 21 16:07 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Officer STEPHENSON BRIAN C

Feb 21 16:07 ET

BridgeBio Pharma | 4: Statement of changes in beneficial ownership of securities-Director Valantine Hannah

Feb 20 16:04 ET

BridgeBio Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-NEIL KUMAR(5.59%)

Feb 16 19:17 ET

BridgeBio Pharma | 144: Notice of proposed sale of securities pursuant to Rule 144

Feb 15 16:11 ET

BridgeBio Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(7.36%)

Feb 13 18:11 ET

BridgeBio Pharma | 5: Annual statement of changes in beneficial ownership of securities-Director Valantine Hannah

Feb 13 16:07 ET